Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Alzheimer's disease (AD) is caused by a series of events initiated by the production and aggregation of the amyloid β-protein (Aβ). In the early stages of the disease, is released in a soluble form then progressively forms oligomeric, multimeric, and fibrillar aggregates, triggering neurodegeneration. Thus, development of inhibitors that initiate reverse aggregation is thought to be a logical approach in treating AD. In this context, we developed β-aminopyrrolidine containing 12 mer peptide 3 which is very potent in inhibiting the aggregation and also reducing (42)-induced cytotoxicity. © 2022 European Peptide Society and John Wiley & Sons, Ltd.


Habbanakuppe D Preetham, Umashankara Muddegowda, Kothanahally S Sharath Kumar, Shobith Rangappa, Kanchugarakoppal S Rangappa. Identification of β-aminopyrrolidine containing peptides as β-amyloid aggregation inhibitors for Alzheimer's disease. Journal of peptide science : an official publication of the European Peptide Society. 2022 Jun;28(6):e3386

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 34981876

View Full Text